Study Comparing Ronde-cel to Other CAR T-Cell Therapies for Lymphoma
This study is looking at a new type of CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) for people with large B-cell lymphoma that has come back or is not responding to treatment. Ronde-cel is a type of immunotherapy that uses your own modified immune cells to fight cancer. It targets two markers on cancer cells, CD19 and CD20. This study will compare ronde-cel to two other approved CAR T-cell therapies, axicabtagene ciloleucel and lisocabtagene maraleucel, which both target CD19. The goal is to see if ronde-cel can help people live longer without their cancer returning. You may be able to join if you are at least 18 years old and have not had CAR T-cell therapy before. The study plans to include about 400 participants.
- Study design
- This is a Phase 3 randomized controlled trial, meaning participants are randomly assigned to receive either ronde-cel or one of the other two approved CAR T-cell therapies. Approximately 400 participants will be enrolled.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed to measure event-free survival for 36 months after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
At a glance
Conditions
Where it's being run
36 sites across 22 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Event free survival36 months
The time interval from treatment initiation until the occurrence of a specific event of interest.